JMP Securities Reiterates “Market Outperform” Rating for Summit Therapeutics (NASDAQ:SMMT)
Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by research analysts at JMP Securities in a research note issued to investors on Monday,Benzinga reports. They currently have a $40.00 price target on the stock. JMP Securities’ target price would suggest a potential upside of 69.35% from the company’s current […]
Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by research analysts at JMP Securities in a research note issued to investors on Monday,Benzinga reports. They currently have a $40.00 price target on the stock. JMP Securities’ target price would suggest a potential upside of 69.35% from the company’s current […]
